Usefulness of the HE4 biomarker as a second-line test in the assessment of suspicious ovarian tumors
Open Access
- 31 May 2013
- journal article
- research article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 288 (6) , 1377-1383
Abstract
Purpose The aim of our study was the evaluation of HE4 usefulness as a test in assessment of ovarian tumors which are suspicious and difficult to classify correctly via subjective ultrasound examination. Methods In this retrospective cohort study 253 women diagnosed with adnexal masses were examined preoperatively. Suspicious tumors (n = 145) were divided into groups of: “probably benign” (n = 70), “uncertain” (n = 34), and “probably malignant” (n = 41). “Uncertain” tumors were also assessed as “benign” (n = 11) or “malignant” (n = 23). The logistic regression model was performed to analyze if the serum marker improves the prediction of a malignant finding and net reclassification improvement (NRI) was calculated to measure diagnostic improvement. Results Within the analyzed group 85 (58.6 %) benign and 60 (41.4 %) malignant tumors were confirmed histopathologically. The comparison of HE4 with subjective ultrasound assessment showed lowered NRI in the entire analyzed group as well as in the groups of tumors classified as “probably benign” or “probably malignant” (NRI = −0.16; P = 0.0139 and NRI = −0.133; P = 0.0489, respectively). The analysis of logistic regression model confirmed that biomarkers do not improve diagnostic accuracy. The difference between areas under ROC for HE4 (0.891) and CA125 (0.902) was not statistically significant (P = 0.760). Conclusions After subjective ultrasound assessment, the addition of the second-line test—HE4 as well as CA125 serum level does not improve diagnostic performance. However, HE4 evaluation satisfies the clinical expectations of diagnostic tools for ovarian tumors and, thus, may be useful to less experienced sonographers.Keywords
This publication has 24 references indexed in Scilit:
- Evaluation of selected ultrasonographic parameters and marker levels in the preoperative differentiation of borderline ovarian tumors and ovarian cancersArchives of Gynecology and Obstetrics, 2012
- Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal massesEuropean Journal of Cancer, 2012
- Designing early detection programs for ovarian cancerAnnals of Oncology, 2011
- OC21.03: Ultrasound imaging compared to a multivariate predictive algorithm combining HE4 and CA 125 (ROMA®) in the pre‐operative assessment of adnexal massesUltrasound in Obstetrics & Gynecology, 2011
- HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseasesTumor Biology, 2011
- HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy AlgorithmBritish Journal of Cancer, 2011
- Extensions of net reclassification improvement calculations to measure usefulness of new biomarkersStatistics in Medicine, 2010
- Comparison of diagnostic accuracy of transvaginal ultrasound with laparoscopy in the management of patients with adnexal massesArchives of Gynecology and Obstetrics, 2009
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- Which extrauterine pelvic masses are difficult to correctly classify as benign or malignant on the basis of ultrasound findings and is there a way of making a correct diagnosis?Ultrasound in Obstetrics & Gynecology, 2006